Premium
Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients
Author(s) -
Alper Özgül M.,
Wong LeeJun C.,
Young Suzanne,
Pearl Michelle,
Graham Steve,
Sherwin John,
Nussbaum Eliezer,
Nielson Dennis,
Platzker Arnold,
Davies Zoe,
Lieberthal Allan,
Chin Terry,
Shay Greg,
Hardy Karen,
Kharrazi Martin
Publication year - 2004
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.9281
Subject(s) - missense mutation , cystic fibrosis transmembrane conductance regulator , cystic fibrosis , exon , biology , mutation , genetic counseling , genetics , allele , genotyping , population , gene , medicine , genotype , environmental health
In ethnic heterogeneous California, complete genetic information is currently lacking to build solid population‐based cystic fibrosis (CF) screening programs because a large proportion of mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR/ABCC7) are still unknown, especially in non‐Caucasian patients. A total of 402 [46 African American+356 Hispanic] Hispanic and African American patients from California CF patient registry were included in this study. Patients with at least one unidentified mutant allele were asked to donate blood samples for further analysis, first by Genzyme Genetics for a panel of 87 known mutations, followed by temporal temperature gradient gel electrophoresis (TTGE) scanning of the entire coding exons of CFTR gene. A total of eight novel mutations; one missense mutation, one splice‐site mutation and six frame‐shift mutations were identified. In addition to the eight novel mutations, 21 distinct rare mutations that are not in the current available commercial mutation panels were identified by TTGE. The overall detection rate was raised to 95.7% for African American and 94.5% for Hispanic. The discovery of recurrent rare and novel mutations improves the diagnosis and care of persons with CF and improves our ability to adequately and equitably provide screening and genetic counseling services to non‐Caucasians. © 2004 Wiley‐Liss, Inc.